Company Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
The company’s CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA.
It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology.
The company’s lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient’s hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells.
It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D.
It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
| Country | Switzerland |
| Founded | 2013 |
| IPO Date | Oct 19, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 393 |
| CEO | Samarth Kulkarni |
Contact Details
Address: Baarerstrasse 14 Zug, 6300 Switzerland | |
| Phone | 41 41 561 32 77 |
| Website | crisprtx.com |
Stock Details
| Ticker Symbol | CRSP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001674416 |
| CUSIP Number | H17182108 |
| ISIN Number | CH0334081137 |
| Employer ID | 47-3173478 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Samarth Kulkarni Ph.D. | Chief Executive Officer and Chairman |
| Dr. Raju Yashaswi Prasad Ph.D. | Chief Financial Officer |
| James R. Kasinger J.D. | General Counsel and Secretary |
| Dr. Naimish Patel C.M., M.D. | Chief Medical Officer |
| Shaun Foy CFA | Co-Founder |
| Dr. Emmanuelle Marie Charpentier Ph.D. | Co-Founder and Scientific Advisory Board Member |
| Dr. Craig C. Mello Ph.D. | Scientific Founder and Advisory Board Member |
| Dr. Chad A. Cowan Ph.D. | Scientific Founder |
| Dr. Matthew Porteus M.D., Ph.D. | Scientific Founder and Advisory Board Member |
| Dr. Daniel G. Anderson Ph.D. | Scientific Founder and Advisory Board Member |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 12, 2026 | 10-K | Annual Report |
| Feb 12, 2026 | 8-K | Current Report |
| Feb 5, 2026 | SCHEDULE 13G/A | Filing |
| Jan 22, 2026 | 144 | Filing |
| Jan 22, 2026 | 144 | Filing |
| Jan 20, 2026 | 144 | Filing |
| Jan 12, 2026 | 8-K | Current Report |
| Jan 6, 2026 | 144 | Filing |
| Dec 22, 2025 | 144 | Filing |